Immunotherapy of human cancers using gene modified T lymphocytes.
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
Vera
Juan F
JF
Center for Cell and Gene Therapy, Department of Medicine, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, 6621 Fannin Avenue, Houston, TX 77030, USA.
Brenner
Malcolm K
MK
Dotti
Gianpietro
G
D000941:Antigens / Q000276:immunology; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000941:Antigens